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Abstract
Neurodegenerative diseases present substantial clinical challenges. Their processes
have been linked with various genetic causes, including mutations of genes encoding
proteins associated with mitochondrial dynamics. Biallelic mutations in SLC25A46 have
been identified as novel causes of a wide spectrum of neurological diseases with reces-
sive inheritance, including optic atrophy, Charcot-Marie-Tooth neuropathy (CMT) type
2A neuropathy, Leigh syndrome, progressive myoclonic ataxia, and lethal congenital
pontocerebellar hypoplasia. SLC25A46 (solute carrier family 25 member 46) is a mem-
brane transit protein that is expressed in the mitochondrial outer membrane where it
plays a major role in mitochondrial dynamics and cristae maintenance. This chapter
presents recent findings on: (1) the clinical heterogeneity of SLC25A46-related neurop-
athies; (2) the SLC25A46 mutation spectrum and associated genotype-phenotype corre-
lation; and (3) pathophysiological functions of SLC25A46 as characterized in cells and
mouse models. A better understanding of the etiology of SLC25146-linked diseases will
elucidate therapeutic perspectives.
Keywords: neurodegeneration, SLC25A46, mitochondrial dynamics, optic atrophy,
CMT-2 neuropathy, pontocerebellar hypoplasia
1. Introduction
Mitochondria have long been recognized as critical organelles for cellular energy generation.
They produce 90% of neuronal adenosine triphosphate (ATP), which is continuously required
for maintaining the complex morphology and specialized functions of neurons, including elec-
trical excitability and synaptic transmission [1], and are regenerated continuously in postmitotic
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neurons through biogenesis. In addition to undergoing the dynamic processes of mitochondrial
fission and fusion, mitochondria are transported bidirectionally within neurites, in which they
are distributed purposefully, facilitating energy transmission over long distances to meet local
demands and, when necessary, undergo controlled degradation by mitophagy [2, 3]. Thus,
mitochondrial dynamics play critical roles in neuronal homeostasis and survival.
Recent evidence suggests that abnormal mitochondrial dynamics may contribute to both
familial and sporadic neurodegenerative diseases [4]. Most proteins related to mitochondrial
dynamics are encoded by genes in the nucleus. Mutations in such nuclear-encoded genes can
cause monogenic disorders in which mitochondrial dysfunction is unequivocally central to the
pathogenesis of the disease. For example, mutations in MFN1/2 and OPA1 cause Charcot-
Marie-Tooth neuropathy (CMT) type 2A [5–7] and autosomal dominant optic atrophy (ADOA)
[8–10], respectively. A dominant negative allele of DRP1 was identified in a neonate with a
lethal mitochondrial and peroxisomal fission defect associated with abnormal brain develop-
ment, optic atrophy, and various other congenital anomalies [11]. Defects in proteins involved
in axonal transport have also been identified in patients with CMT and related neuropathies
[12–14]. In addition, there is increasing evidence linking mitochondrial dysfunction to neuro-
nal loss in age-related neurodegenerative disorders, including Alzheimer’s disease and
Parkinson’s disease [15, 16].
Recent studies have implicated the 46th isoform of subfamily A of the solute carrier (SLC) family
25, termed SLC25A46, in mitochondrial dysfunction pathology. SLC25A46 is a mitochondrial
outer membrane protein that was shown recently to be involved in mitochondrial dynamics,
either playing a role in mitochondrial fission or serving as a regulator of mitofusin (MFN)1/2
oligomerization [17, 18]. Disorders caused by recessive SLC25A46 mutations were defined
recently as a new syndrome (introduced and elaborated in Section 3.1) that has a broad clinical
spectrum of neurological phenotypes, including peripheral neuropathy, early-onset optic atro-
phy, cerebellar degeneration, and congenital pontocerebellar hypoplasia (PCH), with variable
ages of onset and severities [17, 19–26]. In this chapter, we will focus on the phenotypic and
genetic characteristics of SLC25A46-related neurological diseases and our current understanding
of the pathophysiological mechanisms linking dysfunctional SLC25A46 to neurodegeneration.
2. SLC25 family and the discovery of SLC25A46
SLC25A46 belongs to the solute carrier family 25 (SLC25), a superfamily that contains 53
nuclear-encoded mitochondrial carrier proteins in humans [27]. SLC25 members are character-
ized by the presence of three tandem repeats of about 100 amino acids, each containing two
transmembrane alpha helices linked by a large loop [28]. The mature carrier protein thus
consists of six transmembrane helices that form an aqueous pore and have a highly conserved
consensus sequence, P-X-[D/E]-X-X-[R/K], at the C-terminal ends of the three odd-numbered
transmembrane alpha helices, whose charged residues form salt bridges that close the pore on
the matrix side [29]. SLC25 proteins may shuttle a variety of solutes across the mitochondrial
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membrane to participate in various metabolic pathways [30]. Although common mechanisms
of substrate translocation have been proposed, SLC25 members vary greatly in their size, the
nature of substrates they transport, the modes of transport employed, and the driving forces
they employ [30–32].
A number of genetic conditions associated with SLC25 mitochondrial transporters have been
characterized biochemically and genetically [33]. SLC25 members mediate a variety of cellular
functions, and mutations in SLC25 genes have been linked to various defects, such as carnitine/
acylcarnitine carrier deficiency (OMIM 212138), HHH syndrome (OMIM 238970), aspartate/
glutamate isoform 1 and 2 deficiencies (OMIM 612949, 603471, 605814), congenital Amish
Figure 1. Schematic diagram of SLC25A46 structure and its interactions. (A) SLC25A46 consists of six conserved trans-
membrane alpha helices. (B) 3D structure of SLC25A46. (C) Potential interactions of SLC25A46 with dynamic proteins.
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microcephaly (OMIM 607196), neuropathy with bilateral striatal necrosis (OMIM 613710),
congenital sideroblastic anemia (OMIM 205950), neonatal epileptic encephalopathy (OMIM
609304), and citrate carrier deficiency (OMIM 190315) [33]. These disorders are characterized
by specific metabolic dysfunctions related to the role of the particular carrier that has been
affected. Most disease-related SLC25 members have been characterized in terms of substrate
identification and associated metabolic pathways, with the exception of two orphan SLC25
members, namely SLC25A38 and SLC25A46 [33].
SLC25A46 was first mapped to chromosome 5 by genomic sequence analysis in 2006 [27]. Its
location was further refined to chromosome 5q22.1 based on sequence alignment with NCBI’s
standard reference human assembly sequence, that is, the Genome Reference Consortium
Human genome build 38. The largest transcript isoform of SLC25A46 contains eight exons,
which encode a 418-amino acid protein. Quantitative real-time polymerase chain reaction (PCR)
experiments in rodents have demonstrated variable expression of SLC25A46 in all tissues exam-
ined, with the highest levels occurring in the hindbrain, spinal cord, and coronal brain sections
containing the corpus callosum, fornix, optic chiasm, thalamus, hypothalamus, midbrain, pons,
and cerebellum, with particularly high levels in mouse embryo cerebellum [27].
Given the typical SLC25 molecular structure, the primary sequence of the SLC25A46 protein has
been predicted to form six conserved transmembrane alpha helices, TM1–TM6, spanning a
region between amino acids 100–418 (Figure 1) [22]. However, the otherwise highly conserved
P-X-(D/E)-X-X-(R/K) consensus sequence characteristic of SLC25 proteins is altered in SLC25A46.
Moreover, the N-terminus of SLC25A46 is about five times longer than that of other members of
the family (100 vs. <20 amino acids). These unusual characteristics suggest that SLC25A46 is
unlikely to have a conventional metabolite carrier function. Recently, studies have proposed that
unlike most SLC25 members that are located in the inner mitochondrial membrane, SLC25A46
may be anchored to the outer mitochondrial membrane where it may act as a regulator of
mitochondrial dynamics rather than as a substrate transporter.
3. Clinical phenotypes of SLC25A46-related diseases
3.1. Hereditary motor and sensory neuropathy type VIB (HMSN6B)
In 2015, recessive mutations in SLC25A46 in eight patients from four unrelated families of
various ethnic origins were first reported. The proband phenotypes encompassed ADOA-like
optic atrophy, CMT-like axonal peripheral neuropathy, and cerebellar atrophy with a variable
age of onset and disease course (Table 1) [17]. This new neurodegenerative syndrome is now
defined as HMSN6B in OMIM (OMIM: 616505). ADOA and CMT type 2 are hereditary
neurodegenerative disorders commonly caused by mutations in the mitochondrial fusion
genes OPA1 andMFN2, respectively. However, both diseases lack a genetic diagnosis in up to
60% of patients due to genetic heterogeneity [34, 35].
SLC25A46 provides a new locus in genetic testing for patients with ADOA and CMT-like
phenotypes. Indeed, four independent clinical reports published in 2016 and 2017 identified
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ID SLC25A46
mutations
SLC25A46
proteins
Age of
onset
Age of death Optic
atrophy
Peripheral
neuropathy
Cerebellar
or
brainstem
atrophy
Hypotonia
or
myopathy
Ataxia Lactate Other features Mitochondrial
dynamics
UK family
Abrams et al.
[17]
c.165_166insC;
c.746G>A
p.His56fs*94;
p.Gly249Asp
5 y/8 y Alive (40 y/43 y) + +    Normal Normal CSF examination,
oxidative enzyme activity,
no ragged red fibers.
n.k.
PL family
Abrams et al.
[17]
c.1005A>T p.Glu335Asp 1 y/2 y Alive
(13 mo/11.5 y)
+ + + + + ↑ Developmental delay, 3-
MG ↑ in urine.
Increased
mitochondria.
IT family
Abrams et al.
[17]
c.1018C>T p.Arg340Cys 2 y Alive (51 y) + + + + + ↑ CK ↑(225, NR<170 U/L),
lactic acid at upper end of
normal range.
Hyperfilamentous.
US family
Abrams et al.
[17]
c.882_885dupTTAC;
c.998C>T
p.
Asn296fs*297;
p.Pro333Leu
Prenatal 105 d + + + + n.k. n.k. Facial and hand
dysmorphism, meconium
aspiration.
n.k.
Moroccan
family
Nguyen et al.
[21]
c.283+3G>T p.? Prenatal 7 d + n.k. + + n.k. ↑ Club foot posture, lactate-
to-pyruvate ratio ↑ and all
individual complexes ↓ in
fibroblasts.
Mitochondrial
fragmentation.
Pakistani
origin family
Charlesworth
et al. [19]
c.413T>G p.Leu138Arg n.k. Alive (15 y/20 y) + + + + + n.k. Comprised exotropia,
difficulty initiating
saccades, spasticity,
scoliosis. Old brother with
mild phenotypes.
n.k.
Saudi family
Sulaiman
et al. [26]
c.775C>T p.Arg259Cys 28 y Alive +   + n.k. Normal No ragged red fiber or
cytochrome c deficiency,
intact sensation and
coordination,
unremarkable
acylcarnitine profile,
amino acids, CK and urine
organic acids.
Occasional
enlarged
mitochondria.
Tunisian
family
Hammer et al.
[23]
c.1018C>T p.Arg340Cys 1 y/6 y Alive (22 y/19 y) + +  n.k. + n.k. Dysarthria, gait instability,
Babinski sign, abolished
Achilles reflexes, finger-
nose dysmetria, severe
sensorimotor
demyelination.
n.k.
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ID SLC25A46
mutations
SLC25A46
proteins
Age of
onset
Age of death Optic
atrophy
Peripheral
neuropathy
Cerebellar
or
brainstem
atrophy
Hypotonia
or
myopathy
Ataxia Lactate Other features Mitochondrial
dynamics
Algerian
family 1
Hammer et al.
[23]
c.1018C>T p.Arg340Cys 2 y Alive (31 y) + +  n.k. + n.k. Subtle white matter
changes in cerebellum,
increased tendon reflexes,
no Achilles reflex, positive
Hoffmann sign, no
Babinski sign.
n.k.
Algerian
family 2
Hammer et al.
[23]
c.479G>C p.Trp160Ser 23 y Alive (26 y)  n.k. n.k. n.k. + n.k. Abolished vibration sense,
at ankles, nystagmus and
saccadic pursuit, scoliosis.
n.k.
Family 1
Wan et al. [22]
c.1022T>C p.Leu341Pro Prenatal 14 d/28 d n.k. n.k. + + n.k. Normal PCH, severe global
developmental delay,
normal respiratory chain
enzymes in muscle and
liver.
Increase in
mitochondrial
length.
Family 2
Wan et al. [22]
g.chr5:110738771_
11074670del
p.? Prenatal 42 d + + + + n.k. ↑ PCH, occasional myoclonic
jerks; EEG: generalized
slowing with abnormal
theta rhythm, no epileptic
discharges, sibling with
same phenotype.
n.k.
Dutch family
Dijk et al. [25]
c.691C>T
g.chr5:110742638_
110745029del
p.Arg231*;
p.?
Prenatal 1 d + n.k. + + n.k. n.k. PCH, all three children
died within 1 day after
birth, lack of spontaneous
respiration, profound
muscle weakness.
Convulsion, spinal motor
neuron degeneration.
n.k.
German
family
Braunisch
et al. [24]
c.736A>T p. Arg 246 * Prenatal 1 d/23 d n.k. n.k. + + n.k. ↑ PCH, seizures, EEG: low
amplitudes with sharp
waves, epileptiform
discharges without clinical
equivalents, thrombocytes
↑, lung hypoplasia,
n.k.
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ID SLC25A46
mutations
SLC25A46
proteins
Age of
onset
Age of death Optic
atrophy
Peripheral
neuropathy
Cerebellar
or
brainstem
atrophy
Hypotonia
or
myopathy
Ataxia Lactate Other features Mitochondrial
dynamics
bradycardia at birth, green
amniotic fluid.
Italian family
Braunisch
et al. [24]
c.42C>G;
c.462+1G>A
p.Tyr14 *;
P. ?
Prenatal 1 d/18 d n.k. n.k. + + n.k. n.k. PCH, floppy infant, little
respiratory effort and
voluntary movements;
EMG: neurogenic lesion;
loss of spinal motor
neurons, normal CK levels,
serum transferrin IEF, two
siblings were hypotonic
and died immediately after
birth.
n.k.
French
Canadian
family
Janer et al.
[20]
c.425C>T p.Thr142Ile;
(instable
protein)
Birth 15 mo + n.k. + + n.k. ↑ Leigh syndrome,
psychomotor delay,
growth retardation, mild
spastic diplegia; motor
delay; fever, convulsion,
gasping respirations,
bilateral intranuclear
ophthalmoplegia,
hyperreflexia, mild
spasticity.
Mitochondrial
hyperfusion in
fibroblast.
Note: y, year; mo, month; d, day; n.k., not known; ↑, increase.
Table 1. Clinical phenotypes associated with SLC25A46 mutations.
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homogenous SLC25A46mutations in an additional nine patients (age range, 7 days to 28 years)
from five unrelated families who presented with neurological phenotypes similar to the core
features of HMSN6B. Among these nine patients, eight had optic atrophy (the exception was a
patient with an age of onset 23 years) and eight had cerebellar atrophy (the exception was a
28-year-old patient without remarkable cerebellar atrophy or axonal neuropathy) (Table 1) [19,
21, 23, 26]. Beyond the key clinical features of optic atrophy, peripheral neuropathy, and
cerebellar atrophy, the presently documented population of 17 patients with HMSN6B (or
an HMSN6B-like condition) exhibited other clinical symptoms sporadically, including ataxia,
hypotonia, myoclonus, dysmetria, nystagmus, speech difficulties, abnormal brain imaging, and
elevated lactic acid (Table 1). The clinical manifestations, medical examination findings, and
differential diagnoses for these patients were strongly suggestive of a progressive mitochondrial
disorder.
3.2. SLC25A46-related PCH and Leigh syndrome
A recent study reported the identification of SLC25A46 loss-of-function mutations in four
patients from two unrelated families with a diagnosis of severe congenital PCH, leading to
very early mortality [22]. Then, two independent groups reported an additional seven patients
from three unrelated families with severe PCH associated with truncating mutations of
SLC25A46 (Table 1) [24, 25].
PCH is a rare, heterogeneous group of prenatal onset neurodegenerative disorders, mainly
(but not exclusively) affecting the cerebellum and pons. The current PCH classification scheme
includes 10 distinct PCH subtypes defined by clinical features and genetic etiology. PCH1 is
distinguished from the other PCH subtypes by its association with spinal muscular atrophy
due to spinal motoneuron degeneration; it often leads to early death. All patients with obvious
loss-of-function SLC25A46 genotypes in the literature suffered severe lethal congenital PCH,
presenting with the phenotypic hallmarks of cerebellar and brainstem degeneration as well as
spinal muscular atrophy, respiratory failure, early death, occasional optic nerve atrophy, and
axonal neuropathy. Based on these features, SLC25A46-associated PCH could be classified as
PCH1, and perhaps a new PCH1 subtype, PCH1D, clinically distinguished from other PCH1
subtypes (mutations in VRK1, EXOSC3, and EXOSC8 are associated with PCH1A, PCH1B,
and PCH1C, respectively) [25]. However, the most severe clinical presentation associated with
SLC25A46mutations is probably not restricted to PCH. A homozygous SLC25A46mutation that
resulted in the complete absence of the protein was identified recently in a terminally ill child
with progressive brain lesions consistent with those seen in Leigh syndrome (Table 1) [20].
Cerebellar and brainstem atrophy are shared phenotypic features of PCH, Leigh syndrome,
and most variant SLC25A46-related HMSN6B cases. Meanwhile, optic nerve and peripheral
nerve axonal pathology are seen consistently in HMSN6B. Features that are prominent in later-
onset cases might be overlooked or not assessed in neonatally lethal cases. Thus, SLC25A46-
related PCH or Leigh syndrome could be extreme forms of HMSN6B.
To sum up, SLC25A46-related neurological disease has high clinical heterogeneity. Patients
with biallelic SLC25A46 mutations show high phenotypic variability with respect to age of
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onset, clinical features, and disease course. The severity of presentation even varies between
siblings. The phenotype spectrum ranges from severe disease at birth with early death to
manifestation in late childhood with survival beyond 50 years of age.
4. Mutation spectrum of SLC25A46 and genotype-phenotype correlation
4.1. Mutation spectrum of SLC25A46
The SLC25A46 gene, located on chromosome 5q22.1, spans approximately 27 kb and is com-
posed of eight exons. The main protein isoform has 418 amino acids and is encoded by a
1257-nucleotide-long open reading frame. Since SLC25A46 mutations associated with neuro-
logical disease were first reported in 2015, more than 28 patients with various mutations from
16 unrelated families have been diagnosed genetically, most by whole-exome sequencing,
leading to the discovery of a total of 18 pathogenic mutations in the last 2 years (Figure 2). Of
these, 50% are missense mutations; 16.7% are nonsense mutations; 11.1% are splice variants;
and 22.2% are micro-deletions, insertions, or duplications. The mutation sizes range from a
single nucleotide polymorphism to a 2.4-kb deletion. Although some mutations have been
found in all exons except exons 2, 6, and 7, 50% of the mutations are located in exon 8, the
largest exon, which accounts for half of the SLC25A46 open reading frame (Figure 2).
Although there is no suspected mutation hotspot site, the c.1081C>T variant was observed in
3 of 16 independent families (Table 1). The identification and genetic diagnosis of additional
cases in the future may reveal a SLC25A46mutation pattern.
4.2. Genotype-phenotype correlation
A systemic genotype-phenotype analysis of all available cases indicates that phenotype sever-
ity correlates strongly with the magnitude of SLC25A46 protein level reduction caused by each
Figure 2. Schematic diagram of reported pathogenic SLC25A46 variants. Exons 1–8 are represented by blue blocks.
Mutations are color coded as follows: red, nonsense and missense mutations that would be expected to destabilize the
protein; blue, micro-deletions/insertions/duplications; orange, splice-site mutations; and black, regular missense
mutations.
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mutation. As shown in Table 1, very severe SLC25A46-related disease has been linked to
mutations that yield markedly reduced SLC25A46 levels, including homozygous or
compound heterozygous nonsense mutations, (c.691C>T, p.Arg231*; c.736A>T, p.Arg246*;
c.42C>G, p.Tyr14*), a splice site variant (c.462+1G>A), and a micro-deletion (g.chr5:
110738771_11074670del). In addition, Wan et al. and Janer et al. verified that the three
missense mutations c.1022T>C (p.Leu341Pro), c.998C>T (p.Pro333Leu), and c.425C>T (p.
Thr142Ile) destabilize the protein without nonsense-mediated mRNA decay, causing a
marked loss of SLC25A46 function. Such protein-depriving mutations lead to severe clinical
symptoms of PCH or Leigh syndrome. In contrast, missense mutations of SLC25A46 that
are associated with normal or mildly reduced protein levels tend to result in a relatively
mild phenotype. For instance, stable expression of the p.Gly249Asp mutant protein pro-
duces low-severity manifestations of optic atrophy spectrum disorder [17, 22] (Table 1).
Thus, the more stable, functional, and abundant the mutant protein, the less severe the
clinical manifestations.
In conclusion, the main molecular causes of SLC25A46-related neurological disease appear to
be SLC25A46 loss of function or deficiency. The recessive inheritance pattern observed in all
pathogenic SLC25A46 mutation-affected individuals and families thus far contrast with the
dominant inheritance pattern observed with other mitochondrial dynamic genes, including
OPA1, MFN1/2, and DRP1, for which haplo-insufficiency and dominant negative effects are
observed [8, 36, 37].
5. Pathophysiological function of SLC25A46
In the last 2 years, a series of experiments aiming at resolving the function of SLC25A46 and
the pathogenesis of SLC25A46-associated diseases were conducted. Primary cultures of skin
fibroblasts from HMSN6B patients (including PCH or Leigh syndrome patients) have been
studied to investigate the pathophysiology of the diseases. Simultaneously, mutant
SLC25A46 alleles or SLC25A46-targeted RNA-interference molecules were transfected into
common cell lines (e.g., COS-7, HeLa, HEK293T, and HCT116) to study the consequences of
the mutations or protein knock-down in a homogeneous genetic background. Finally,
zebrafish, murine, and bovine models have been employed to examine the pathophysiolog-
ical effects of SLC25A46 mutations in vivo (Table 2).
5.1. Function of SLC25A46 in mitochondrial dynamics
In silico analysis led to the identification of a SLC25A46 homolog in yeast, namely Ugo1. The
Ugo1 protein is a modified mitochondrial solute carrier expressed in the mitochondrial outer
membrane that operates as a mitochondrial fusion factor and interacts physically with Mgm1
(homolog of human OPA1) and Fzo (homolog of human MFN2) [38]. A succession of studies
in cells demonstrated consistently that, like Ugo1, MTCH1, and MTCH2, SLC25A46 also
localizes to the mitochondrial outer membrane [17, 20, 22].
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Animal
species
SLC25A46
mutations
SLC25A46 proteins Age
of
onset
Age of
death
Optic
atrophy
Peripheral
neuropathy
Ataxia Degeneration
in cerebellum
/brainstem
Other features Mitochondrial
dynamics
Bovine
Duchesne
et al. [43]
c.376C>T p. R126C 1 mo. Euthanasia
around 2–
3 mo.
— + + + Degenerative
lesions both in
gray matter
and white
matter;
demyelination
in certain
peripheral
nerves.
Elongated
mitochondria
with abnormal
cristae.
Tg/ FVB/
N mouse
Duchesne
et al. [43]
Tg18: indel
12 bp;
Tg26:
del 75 bp
p.
Val122Leu123delinsATIIYI;
p.Ala108fs*159
2 w 3–4 w —  +  Impaired
growth, small
intestine,
thymus, spleen
and liver,
severe
hypoglycemia;
low plasma
iron
concentrations
combined with
high ferritin.
Elongated
mitochondria
with abnormal
cristae.
atc/atc
C57BL/6 J
mouse
Terzenidou
et al. [42]
c.283C>T p.Gln95fs* 2 w 5 w + + + + Growth
retardation,
severe thymic
and splenic
hypoplasia,
compromised
Purkinje cell
dendritic
arborization
and reduced
synaptic
connectivity,
RGC
Atypical
mitochondria
in Purkinje
cells.
Neurodegenerative Diseases Associated with Mutations in SLC25A46
11
Animal
species
SLC25A46
mutations
SLC25A46 proteins Age
of
onset
Age of
death
Optic
atrophy
Peripheral
neuropathy
Ataxia Degeneration
in cerebellum
/brainstem
Other features Mitochondrial
dynamics
aberrations,
improper
neuromuscular
junction.
Slc/
B6D2
mouse Li
et al. [39]
c.992_1037del p.Leu331fs*346 2 w 2–8 w + + + + Purkinje cell
loss and
dendritic
abnormalities,
degeneration in
striatum,
corpus
callosum and
spinal cord;
axon
degeneration
and
demyelination.
Enlarged or
ring/C-shaped
mitochondria.
Note: mo represents month; w the week.
Table 2. Clinical phenotypes associated with mutant SLC25A46 animal models.
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Knock down of SLC25A46 in various cell lines by different research groups caused mitochon-
drial hyperfusion and abnormal cristae architecture visualized with fluorescent staining and
electron microscopy [17, 20, 22]. In concordance, in an ultrastructural study of a SLC25A46
knock-out mouse model, we observed enlarged mitochondria with swollen cristae in Purkinje
cell (PC) dendrites and sciatic nerves (Table 2) [39]. Hyperfused mitochondria consequent to
SLC25A46 loss was unexpected because loss of Ugo1 function usually results in mitochondrial
fission; however, it should be noted that strikingly similar cristae architecture abnormalities
from loss of function are common to both genes [38, 40, 41]. Interestingly, in SLC25A46 mutant
Purkinje cell bodies, ring-shaped or C-shaped mitochondria (a rarely reported morphology)
were more commonly observed than hyperfused mitochondria [39, 42]. Furthermore, mito-
chondria were found to have an abnormal distribution and impaired movement within
mutant Purkinje cells in a primary culture of mouse cerebellar cells [39]. These findings
confirm that SLC25A46 plays an important role in the regulation of mitochondrial dynamics,
including mitochondrial fusion/fission, distribution, and movement, as well as the mainte-
nance of cristae architecture. Regarding the molecular actions of SLC25A46 in the balance of
mitochondrial dynamics, recent research findings present three possible explanations: (1)
SLC25A46 may act as an independent pro-fission factor; (2) SLC25A46 may serve as a regula-
tor by interacting with mitochondrial fusion machinery, such as through an association with
MFN1/2 oligomerization; and (3) SLC25A46 may regulate mitochondrial dynamics through its
functions in lipid transfer between the endoplasmic reticulum (ER) and mitochondria.
In an inter-institution collaborative exploratory study employing immunoprecipitation assays
and mass spectrometry analysis, there was no evidence of SLC25A46 interacting with MFN2
or OPA1 in HEK293T cells, but rather SLC25A46 was observed forming a complex with
mitofilin that was independent of MFN2 [17]. Furthermore, overexpression of wild-type
SLC25A46 protein led to mitochondrial fragmentation and disruption of the mitochondrial
network. Thus, SLC25A46 was proposed to act as a pro-fission factor [17]. In contrast, two
subsequent studies using similar immunoprecipitation approaches in patient fibroblasts and
two cell lines (HEK293Twith stable wild-type SLC25A46 expression and LAN5 neuronal cells)
showed SLC25A46 interactions with proteins involved in fission and fusion, including MFN1/
2 and OPA1, as well as with components of the MICOS (mitochondrial contact site and cristae
organizing system) complex (Figure 1) [18, 20]. Moreover, decreased expression of SLC25A46
resulted in increased stability and oligomerization of MFN1 and MFN2 in association with
mitochondria, thus promoting mitochondrial hyperfusion [18]. In SLC25A46 knock-out mice,
two independent mass spectrometry studies yielded opposite results regarding the interaction
between SLC25A46 and common dynamic proteins [42, 43]. Hence, although it seems reason-
able that SLC25A46 would have interaction relationships with MFN1/MFN2 and the MICOS
complex similar to those of Ugo1, further studies are needed to resolve its molecular mecha-
nisms given the current conflicting results in the literature.
MFN2 tethers the ER to the mitochondrial network, suggesting that the ER may have a
physical relationship with the mitochondrial network [44]. SLC25A46 has also been shown to
interact with all nine components of the endoplasmic reticulum membrane complex (EMC)
[18, 20], an ER protein complex recently shown to be necessary for phospholipid transfer from
the ER to mitochondria in yeast. Most mitochondrial phospholipid species were altered
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dramatically by the loss of SLC25A46, indicating that SLC25A46 provides direct coupling of
lipid flux between the ER and mitochondria at outer-inner mitochondrial membrane contacts
[20]. Meanwhile, endoplasmic reticulum chaperone BiP (a.k.a. 78 kDa glucose-regulated pro-
tein), which acts at the ER-mitochondria interface under stress conditions and is considered as
a major regulator of the ER, was down-regulated in SLC25A46 knock-out mice [43]. These
findings support the notion that the facilitation of lipid flux at ER contact sites may be a
primary function of SLC25A46.
Studies implicating OPA1 and the MICOS complex in the maintenance of cristae architecture
are compelling, but it is unclear how they may interact [45]. The observation that SLC25A46
interacts with OPA1 and MIC60, the major MICOS organizer, provides a molecular link that
may integrate their functions in modulating cristae architecture [18, 20].
It now seems likely that SLC25A46 may possess multiple homeostatic functions in mitochon-
drial dynamics. Further studies are expected to reveal more refined details of the pathophys-
iological functions of SLC25A46, such as which domain interacts with dynamic proteins and
which domain recognizes and communicates with the ER.
5.2. Consequences of SLC25A46 dysfunction on mitochondrial metabolism
Disorganization of cristae leads to disruption of the assembly of the respiratory supercomplexes
that mediate oxidative phosphorylation, which reduces the activity of their components (i.e.,
respiratory complexes I–V) and, thus, diminishes respiration efficiency [46, 47]. Mitochondrial
metabolism is disrupted in both patients with mutant SLC25A46 alleles and animal models of
disrupted SLC25A46. Fibroblasts from patients harboring mutant SLC25A46 showed varying
extents of decreased oxygen consumption rate and glycolytic shift (decreased oxygen consump-
tion rate-to-extracellular acidification rate ratio), consistent with the increased lactate levels
indicated by magnetic resonance spectroscopy (MRS) [17]. Moreover, siRNA-mediated suppres-
sion of SLC25A46 in control fibroblasts phenocopied the basal oxygen consumption defect
observed in the cells of patients with mutant SLC25A46, confirming a specific function of
SLC25A46 in respiration [20]. Given the specificity of each tissue and each cell type in
responding to physiological stresses and mutations, mitochondria isolated from the cerebellum
of SLC25A46 knock-out mouse displayed a remarkable decrease in the activities of respiratory
complexes I–IV, and thus a dramatically reduced ATP production potential [39]. Taken together,
these observations support the hypothesis of an energetic defect being a principal cause of
SLC25A46-related neurological disease.
5.3. SLC25A46 dysfunction in pathology
Mitochondrial pathobiology has long been linked to the pathogenesis of neurodegenerative
diseases, in part because neurons are highly dependent upon mitochondrial metabolism.
Autopsy on a pair of deceased siblings who died due to SLC25A46 mutations showed a very
small cerebellum, as well as degenerative changes in the inferior olive nucleus. Histology of the
cervical spinal cord illustrated loss and ongoing degeneration of spinal motoneurons in the
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medial anterior horn at all levels from the cervical to the lumbar region. Rectus femoris muscle
biopsies showed severely atrophied muscle fibers of all types, without type grouping [48].
For now, most anatomical and histological analyses for SLC25A46-related diseases are based
on animal models. Four SLC25A46 mutant mammalian models have been discovered or
designed, including a calf model and 3 mouse models with different genetic backgrounds
(Table 2). Turning calf syndrome, a neurodegenerative disease, is characterized during mas-
sive inbreeding in cattle. Genetic study determines that this disease resulted from a single
substitution in the coding region of the SLC25A46 [43]. All affected calves manifested early
onset of ataxia, especially of hind limbs, and paraparesis (2–6 weeks old). Despite symptomatic
care, nervous symptoms progressed over the next months, leading to repetitive falls and
ultimately resulting in permanent recumbency and inevitably euthanasia. Characteristic
degenerative microscopic lesions were found in both gray matter (brainstem lateral vestibular
nuclei and spinal cord thoracic nuclei) and white matter (dorsolateral and ventromedial funic-
uli of the spinal cord) regions of the central nervous system, as well as demyelination of some
peripheral nerves [49]. Electron microscopy confirmed this neuropathy phenotype, revealing
discrete demyelinating lesions and some enlarged nodes of Ranvier.
Three SLC25A46 knock-out mouse models with different genetic backgrounds, including FVB/
N, C57BL/6J, and B6D2, were generated, respectively (Table 2). In spite of various mutation
positions and sizes, three mouse lines displayed very similar phenotypes, including growth
delay, progressive ataxia, optic atrophy, short life span, which recapitulated the pathological
state in human. Further histopathologic studies have shown tissue- and cell-specific lesions in
both the central nervous system and peripheral nervous system (Table 2).
Although macroscopic examination showed no overt abnormalities in the gross anatomy of
mutant brain, histological staining revealed markedly reduced cerebellums, with Purkinje cells
(PCs) that had stunted dendrites and were reduced in number. Degeneration (evidenced by
Fluoro-Jade C dye) was selectively present in mutant PCs [39]. Examination via electron
microscopy (EM) revealed that degenerated PC dendrites exhibited disorganized cytoskeleton,
often containing remnants of mitochondria and other organelles. Numerous atypical mito-
chondria with cytoplasmic inclusions were found both in the soma and dendrites of PCs. In
addition, a significant reduction in vGlut1 and vGlut2 immunoreactivity both in PCs and
molecular layer indicated a paucity of glutamatergic synapses in mutant mice [42]. Apart from
PCs, degenerative signals were also aggregated in the vestibular nucleus of brainstem, deep
cerebellar nuclei, the striatum, the corpus callosum, and the spinal cord, but not in other parts
of the brain [39]. The neurodegeneration was associated with astrogliosis and microgliosis in
the cerebellum and spinal cord, indicating high levels of neuroinflammation [39, 42]. These
observations suggest that although SLC25A46 mRNA is transcribed in most neural tissues,
SLC25A46 may have a tissue- or cell-specific function. Interestingly, mice with conditional
knock-out MFN2 or DRP1 mutations showed a similar phenomenon, with major changes in
cerebellar Purkinje cells, whereas granule cells seemed to be spared [50]. It is not yet known
why specific neurons are selectively affected by mitochondrial dysfunction. It could be that a
large neuronal size makes particular neurons susceptible; Purkinje cells are one of the largest
neuron types in the brain with long axons and extremely extensive dendritic branches. Their
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complex architecture requires the transport and distribution of highly organized organelles,
including mitochondria.
Aged SLC25A46 mutant mice displayed enhanced hind limb clasping reflex andmuscle atrophy,
suggesting potential peripheral neuropathy. Acquiring compound muscle action potentials
(CMAPs) reduced in mutant sciatic nerve measured by electromyography (EMG) in vivo [39].
Mutant peripheral nerves exhibited sporadic degenerative lesions with local macrophages
containing lipid debris and signs of demyelination. In addition, the size of individual endplates
in mutant mice was significantly reduced. Retarded neuromuscular junction maturation and
improper innervation, early hallmarks of CMT2D, were also documented in mutant muscle
[42]. All of these alterations are indicative of peripheral neuropathy.
Optical coherence tomography (OCT) scanning on retina for live mice revealed that although
the optic discs were grossly normal in terms of retinal appearance, retinas were thinner in aged
SLC25A46 mutant mice [39]. Further quantitative measurements indicated that ganglion cell
complex (GCC) thicknesses, which includes the nerve fiber layer (NFL), ganglion cell layer
(GCL), and inner plexiform layer (IPL), were significantly reduced in adult mutant mice.
Retinal and these reductions were associated with retinal ganglion cell loss and atypically
small optic nerve axons with reduced neurofilament expression, as well as some axons that
exhibited signs of degeneration and demyelination [39, 42]. Pax6+ and GAD65+ GABAergic
amacrine cells—both of which form synapses with retinal ganglion cells—were also signifi-
cantly reduced. These pathological changes are in line with the phenotypic features of ADOA.
Ultrastructural studies revealed dysmorphic mitochondria in both the central and peripheral
nervous systems. Numerous enlarged and round mitochondria with abnormal cristae were
found in Purkinje cell dendrites, while ring- or C-shaped mitochondria were commonly
observed in soma. Peripheral nerve axons also had abnormal round, fused, and aggregated
mitochondria in myelinated and non-myelinated fibers [39, 43].
Given the degeneration in long peripheral axons and distal optic nerves of SLC25A46 knock-
out animal models, the aforementioned findings support the idea that neurons with long
axons or complicated dendrites are more sensitive to abnormal mitochondrial dynamics.
Similar to the findings in mutant Purkinje cells, this sensitivity could also be due to the
impaired transport of hyperfused mitochondria along axons and dendrites, probably due to
their abnormal size and/or reduced ATP availability in the distal portions of long axons
secondary to mitochondrial dysfunction. Further studies are needed to clarify this point.
6. Conclusion
SLC25A46 plays a critical role in mitochondrial dynamics and the maintenance of mitochon-
drial cristae, which are particularly important in neurodevelopment and neurodegeneration.
Loss of SLC25A46 function causes a wide spectrum of neurodegenerative diseases, including
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optic atrophy, peripheral neuropathy, progressive ataxia, Leigh syndrome, and lethal congen-
ital pontocerebellar hypoplasia. In SLC25A46-related neurodegenerative diseases, phenotype
severity correlates strongly with the magnitude of SLC25A46 level deficit observed.
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